Indications |
Oral Pain relief Adult: 8-16 mg daily. Max: 24 mg daily. Oral Osteoarthritis Adult: 12 mg daily in 2-3 divided doses, up to 16 mg daily if needed. Oral Rheumatoid arthritis Adult: 12 mg daily in 2-3 divided doses, up to 16 mg daily if needed. Parenteral Pain relief Adult: 8 mg once or twice daily by IM/IV inj. Max: 24 mg daily. Special Populations: Reduce dose in elderly. |
Contraindications |
Patients with peptic ulceration; severe renal impairment; pregnancy and lactation. |
Warnings / Precautions |
Active infections; asthma; allergic disorders; haemorrhagic disorders; hypertension; impaired renal, hepatic, cardiac function. |
Adverse Reactions |
Abdominal pain, diarrhoea, dizziness, dyspepsia, nausea, vomiting; headache; haematologic disorders; CNS effects; visual disturbance; tinnitus; nephrotoxicity; fluid retention; photosensitivity; alveolitis; pancreatitis; Stevens-Johnson syndrome; toxic epidermal necrolysis; colitis induction/exacerbation; stomatitis; hypertension, palpitation; insomnia, somnolence. |
Drug Interactions |
Increased lornoxicam blood conc when given concomitantly with cimetidine.Enhanced effects of anticoagulants, sulfonylureas, methotrexate, ciclosporin, digoxin. Decreased effects of diuretics, ACE inhibitors. Potentially Fatal: Increased risk of lithium toxicity. See Below for More lornoxicam Drug Interactions |
Mechanism of Actions |
Lornoxicam is an NSAID that is used in musculoskeletal, joint disorders and other painful conditions including postoperative pain. Lornoxicam is a potent inhibitor of both COX-1 and COX-2 enzymes. Absorption: Extensively absorbed from the GI tract. Peak plasma concentration within 1-2 hr (oral) or 25 min (IM). Distribution: 99% bound to plasma proteins. Metabolism: Metabolised to its inactive metabolite. Excretion: Excreted in the faeces (as metabolites) and urine (as unchanged drug). Mean elimination half life of 3-4 hr. |
ATC Classification |
M01AC05 - lornoxicam ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, oxicams. |
Available As |
|
Lornoxicam
Post Review about Lornoxicam Click here to cancel reply.
Drug - Drug Interactions of Lornoxicam
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.